Pharmaceutical

J&J eyes FDA approval for injection-based Tremfya in ulcerative colitis

Johnson & Johnson Innovation Medicine has submitted a request to the FDA to approve Tremfya as a treatment for ulcerative colitis.

Nov 23, 2024 - 06:00
J&J eyes FDA approval for injection-based Tremfya in ulcerative colitis
Johnson & Johnson Innovation Medicine has submitted a request to the FDA to approve Tremfya as a treatment for ulcerative colitis.
Read the original article

Tags:

Previous Article

UK point-of-care production of cell therapies could arrive in 2025

Next Article

“No magic wand” for Novo Nordisk, as CagriSema pen supply rumours swirl

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Purespring secures $105m to start Phase I/II trial of IgAN gene therapy 

Purespring secures $105m to start Phase I/II trial of I...

Oct 10, 2024

NImmune and BioTherapeutics partner on precision medicine development

NImmune and BioTherapeutics partner on precision medici...

Sep 8, 2024

AbbVie’s Q2 2024 net earnings drop to $1.37bn

AbbVie’s Q2 2024 net earnings drop to $1.37bn

Jul 28, 2024